Selected research
Industry Growth & Trends
Global HIV Vaccines Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global HIV Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for HIV Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for HIV Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for HIV Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the HIV Vaccines market include Sanofi, Glaxosmithkline, Paxvax, Janssen Global Services, Inovio Pharmaceuticals, Geovax, Genecure, Bionor Pharma and Argos Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global HIV Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The HIV Vaccines market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global HIV Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to HIV Vaccines.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global HIV Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
HIV Vaccines Market by Company
Sanofi
Glaxosmithkline
Paxvax
Janssen Global Services
Inovio Pharmaceuticals
Geovax
Genecure
Bionor Pharma
Argos Therapeutics
HIV Vaccines Segment by Type
Phase I
Phase II
Phase III
HIV Vaccines Segment by Application
Research Institute
Others
HIV Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HIV Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of HIV Vaccines companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Phase I
- Phase II
- Phase III
Applications
- Research Institute
- Others
Companies covered
- Sanofi
- Glaxosmithkline
- Paxvax
- Janssen Global Services
- Inovio Pharmaceuticals
- Geovax
- Genecure
- Bionor Pharma
- Argos Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global HIV Vaccines Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global HIV Vaccines Market Size by Region (2021-2032)
- 1.4.1 Global HIV Vaccines Market Size by Region (2021-2026)
- 1.4.2 Global HIV Vaccines Market Size by Region (2027-2032)
- 1.5 Key Regions HIV Vaccines Market Size (2021-2032)
- 1.5.1 North America HIV Vaccines Market Size Growth Rate (2021-2032)
- 1.5.2 Europe HIV Vaccines Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific HIV Vaccines Market Size Growth Rate (2021-2032)
- 1.5.4 South America HIV Vaccines Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa HIV Vaccines Market Size Growth Rate (2021-2032)
2 HIV Vaccines Market by Type
- 2.1 Type Introduction
- 2.1.1 Phase I
- 2.1.2 Phase II
- 2.1.3 Phase III
- 2.2 Global HIV Vaccines Market Size by Type
- 2.2.1 Global HIV Vaccines Market Size Overview by Type (2021-2032)
- 2.2.2 Global HIV Vaccines Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global HIV Vaccines Market Size Forecasted by Type (2027-2032)
- 2.3 Global HIV Vaccines Market Size by Regions
- 2.3.1 North America HIV Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe HIV Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific HIV Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America HIV Vaccines Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa HIV Vaccines Market Size Breakdown by Type (2021-2026)
3 HIV Vaccines Market by Application
- 3.1 Type Introduction
- 3.1.1 Research Institute
- 3.1.2 Others
- 3.2 Global HIV Vaccines Market Size by Application
- 3.2.1 Global HIV Vaccines Market Size Overview by Application (2021-2032)
- 3.2.2 Global HIV Vaccines Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global HIV Vaccines Market Size Forecasted by Application (2027-2032)
- 3.3 Global HIV Vaccines Market Size by Regions
- 3.3.1 North America HIV Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe HIV Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific HIV Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America HIV Vaccines Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa HIV Vaccines Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 HIV Vaccines Industry Trends
- 4.2 HIV Vaccines Industry Drivers
- 4.3 HIV Vaccines Industry Opportunities and Challenges
- 4.4 HIV Vaccines Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by HIV Vaccines Revenue (2021-2026)
- 5.2 Global HIV Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global HIV Vaccines Key Company Headquarters & Area Served
- 5.4 Global HIV Vaccines Company, Product Type & Application
- 5.5 Global HIV Vaccines Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global HIV Vaccines Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 HIV Vaccines Players Market Share by Revenue in 2025
- 5.6.3 2025 HIV Vaccines Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sanofi
- 6.1.1 Sanofi Company Information
- 6.1.2 Sanofi Business Overview
- 6.1.3 Sanofi HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sanofi HIV Vaccines Product Portfolio
- 6.1.5 Sanofi Recent Developments
- 6.2 Glaxosmithkline
- 6.2.1 Glaxosmithkline Company Information
- 6.2.2 Glaxosmithkline Business Overview
- 6.2.3 Glaxosmithkline HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Glaxosmithkline HIV Vaccines Product Portfolio
- 6.2.5 Glaxosmithkline Recent Developments
- 6.3 Paxvax
- 6.3.1 Paxvax Company Information
- 6.3.2 Paxvax Business Overview
- 6.3.3 Paxvax HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Paxvax HIV Vaccines Product Portfolio
- 6.3.5 Paxvax Recent Developments
- 6.4 Janssen Global Services
- 6.4.1 Janssen Global Services Company Information
- 6.4.2 Janssen Global Services Business Overview
- 6.4.3 Janssen Global Services HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Janssen Global Services HIV Vaccines Product Portfolio
- 6.4.5 Janssen Global Services Recent Developments
- 6.5 Inovio Pharmaceuticals
- 6.5.1 Inovio Pharmaceuticals Company Information
- 6.5.2 Inovio Pharmaceuticals Business Overview
- 6.5.3 Inovio Pharmaceuticals HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Inovio Pharmaceuticals HIV Vaccines Product Portfolio
- 6.5.5 Inovio Pharmaceuticals Recent Developments
- 6.6 Geovax
- 6.6.1 Geovax Company Information
- 6.6.2 Geovax Business Overview
- 6.6.3 Geovax HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Geovax HIV Vaccines Product Portfolio
- 6.6.5 Geovax Recent Developments
- 6.7 Genecure
- 6.7.1 Genecure Company Information
- 6.7.2 Genecure Business Overview
- 6.7.3 Genecure HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Genecure HIV Vaccines Product Portfolio
- 6.7.5 Genecure Recent Developments
- 6.8 Bionor Pharma
- 6.8.1 Bionor Pharma Company Information
- 6.8.2 Bionor Pharma Business Overview
- 6.8.3 Bionor Pharma HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Bionor Pharma HIV Vaccines Product Portfolio
- 6.8.5 Bionor Pharma Recent Developments
- 6.9 Argos Therapeutics
- 6.9.1 Argos Therapeutics Company Information
- 6.9.2 Argos Therapeutics Business Overview
- 6.9.3 Argos Therapeutics HIV Vaccines Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Argos Therapeutics HIV Vaccines Product Portfolio
- 6.9.5 Argos Therapeutics Recent Developments
7 North America
- 7.1 North America HIV Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America HIV Vaccines Market Size by Country (2021-2026)
- 7.3 North America HIV Vaccines Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe HIV Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe HIV Vaccines Market Size by Country (2021-2026)
- 8.3 Europe HIV Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific HIV Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific HIV Vaccines Market Size by Country (2021-2026)
- 9.3 Asia-Pacific HIV Vaccines Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America HIV Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America HIV Vaccines Market Size by Country (2021-2026)
- 10.3 South America HIV Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa HIV Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa HIV Vaccines Market Size by Country (2021-2026)
- 11.3 Middle East & Africa HIV Vaccines Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst